221 related articles for article (PubMed ID: 10730885)
1. Granulocyte-macrophage colony-stimulating factor-producing tumour vaccines.
Rössner P; Bubeník J; Sobota V; Indrová M; Hájková R; Mendoza L; Jandlová T; Símová J
Folia Biol (Praha); 1999; 45(5):173-7. PubMed ID: 10730885
[TBL] [Abstract][Full Text] [Related]
2. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
Mikysková R; Indrová M; Símová J; Jandlová T; Bieblová J; Jinoch P; Bubeník J; Vonka V
Int J Oncol; 2004 Jan; 24(1):161-7. PubMed ID: 14654953
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors.
Hájková R; Indrová M; Jandlová T; Bubeník J; Reinis M
Folia Biol (Praha); 1999; 45(6):227-31. PubMed ID: 10732718
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
5. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells.
Armstrong CA; Botella R; Galloway TH; Murray N; Kramp JM; Song IS; Ansel JC
Cancer Res; 1996 May; 56(9):2191-8. PubMed ID: 8616871
[TBL] [Abstract][Full Text] [Related]
8. Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines.
Inoue H; Iga M; Nabeta H; Yokoo T; Suehiro Y; Okano S; Inoue M; Kinoh H; Katagiri T; Takayama K; Yonemitsu Y; Hasegawa M; Nakamura Y; Nakanishi Y; Tani K
Cancer Sci; 2008 Nov; 99(11):2315-26. PubMed ID: 18957055
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC
Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137
[TBL] [Abstract][Full Text] [Related]
10. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4.
Wakimoto H; Abe J; Tsunoda R; Aoyagi M; Hirakawa K; Hamada H
Cancer Res; 1996 Apr; 56(8):1828-33. PubMed ID: 8620500
[TBL] [Abstract][Full Text] [Related]
11. Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1.
Tseng SH; Chen Y; Chang CJ; Tai KF; Lin SM; Hwang LH
Clin Cancer Res; 2005 Feb; 11(4):1639-49. PubMed ID: 15746069
[TBL] [Abstract][Full Text] [Related]
12. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
Sandler AD; Chihara H; Kobayashi G; Zhu X; Miller MA; Scott DL; Krieg AM
Cancer Res; 2003 Jan; 63(2):394-9. PubMed ID: 12543793
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF.
Shi FS; Weber S; Gan J; Rakhmilevich AL; Mahvi DM
Cancer Gene Ther; 1999; 6(1):81-8. PubMed ID: 10078967
[TBL] [Abstract][Full Text] [Related]
14. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
[TBL] [Abstract][Full Text] [Related]
15. Replication-defective recombinant Semliki Forest virus encoding GM-CSF as a vector system for rapid and facile generation of autologous human tumor cell vaccines.
Withoff S; Glazenburg KL; van Veen ML; Kraak MM; Hospers GA; Störkel S; de Vries EG; Wilschut J; Daemen T
Gene Ther; 2001 Oct; 8(20):1515-23. PubMed ID: 11704811
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy with tumor vaccine increases the survival of hepatoma-bearing mice.
Chao Y; Shih YL; Cheng HJ; Wei SJ; Chi KH; Yeh SH; Lee SD; Yang WK
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Oct; 62(10):682-9. PubMed ID: 10533297
[TBL] [Abstract][Full Text] [Related]
17. Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant.
Aruga A; Aruga E; Chang AE
Cancer Res; 1997 Aug; 57(15):3230-7. PubMed ID: 9242454
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine.
Kayaga J; Souberbielle BE; Sheikh N; Morrow WJ; Scott-Taylor T; Vile R; Chong H; Dalgleish AG
Gene Ther; 1999 Aug; 6(8):1475-81. PubMed ID: 10467372
[TBL] [Abstract][Full Text] [Related]
19. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ
Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013
[TBL] [Abstract][Full Text] [Related]
20. Induced immunity by expression of interleukin-2 or GM-CSF gene in murine neuroblastoma cells can generate antitumor response to established tumors.
Yoshida H; Tanabe M; Miyauchi M; Kawamura K; Takenaga K; Ohnuma N; Sakiyama S; Tagawa M
Cancer Gene Ther; 1999; 6(5):395-401. PubMed ID: 10505849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]